Plain-English translation of NCT04993690 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called LP-168 to see if it can help people with B-cell lymphoma that has come back or no longer responds to standard treatments. The study will first test different doses of the medication to find the safest and most effective amount, then expand to treat more patients with specific types of lymphoma. Researchers want to understand how well this treatment works and what side effects it may cause.
Many people with relapsed or refractory B-cell lymphoma have limited treatment options after standard therapies stop working, and new approaches are needed. This trial is exploring whether the medication can help patients whose lymphoma has returned or become resistant to previous treatments.
You likely qualify if…
You likely don't qualify if…
You will take the medication by mouth as a daily tablet and come to the clinic regularly for check-ups and blood tests. The study is organized in phases: first, researchers will test increasing doses in small groups of patients to find the safest dose, then they will treat larger groups of patients with specific lymphoma types at that dose. Each treatment cycle lasts 28 days, and you may continue treatment as long as the medication is helping and you are tolerating it well.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Guangzhou Lupeng Pharmaceutical Company LTD.
Enrollment target
~200 participants
Started
July 2021
Primary completion
December 2026
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jun Zhu, MD, PhD
Peking University Cancer Hospital & Institute
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.